Screener
Nektar Therapeutics NKTR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Total non-operating income (expense), net | (4,036) | (1,834) | |
| Loss before provision for income taxes and equity method investment | (43,090) | (46,369) | |
| Provision for income taxes | 64 | 52 | |
| Loss before equity method investment | (43,154) | (46,421) | |
| Loss from equity method investment | (1,750) | (4,461) | |
| Net loss | $ | $$(44,904) | (50,882) |
| Basic and diluted net loss per share | $ | $$(1.82) | (3.62) |
| Weighted average shares outstanding used in computing basic and diluted net loss per share | 24,736,066 | 14,063,402 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's EPS (diluted)?
- Nektar Therapeutics (NKTR) reported EPS (diluted) of -$1.82 in Q1 2026.
- How has Nektar Therapeutics's EPS (diluted) changed year-over-year?
- Nektar Therapeutics's EPS (diluted) increased by 49.7% year-over-year, from -$3.62 to -$1.82.
- What is the long-term trend for Nektar Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Nektar Therapeutics's EPS (diluted) has grown at a -66.5% compound annual growth rate (CAGR), from -$792.07 to -$10.03.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Nektar Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude